Company: TVRD
Filing Date: 2025-01-27
Form Type: S-4/A
Source: 0001104659-25-006050
Chunk: 789

Company: Tvardi Therapeutics, Inc.
Filing Date: 2025-01-27
Form: S-4/A
Chunk 789
---
 ​ 
 December 31, 2022 |
|:-----------------------------------------------------------------------------------------------------|:--|:--|------------------:|:--|:--|------------------:|
| Cash and cash equivalents                                                                            | ​ | $ |            51,775 | ​ | $ |            63,741 |
| Restricted cash, current assets                                                                      | ​ |   |               408 | ​ |   |               408 |
| Restricted cash, long-term assets                                                                    | ​ |   |             1,500 | ​ |   |                 — |
| Total cash, cash equivalents, and restricted cash shown in the Consolidated Statements of Cash Flows | ​ | $ |            53,683 | ​ | $ |            64,149 |

9. Accounts Payable and Accrued Expenses

Accounts payable and accrued expenses consist of the following:

| ​                                   | ​ 
 ​ | ​ |                 ​ 
 December 31, 2023 | ​ | ​ |                 ​ 
 December 31, 2022 |
|:------------------------------------|:--|:--|------------------:|:--|:--|------------------:|
| Accounts payable                    | ​ | $ |            11,583 | ​ | $ |             9,604 |
| Accrued research projects           | ​ |   |             4,343 | ​ |   |             5,200 |
| Accrued compensation and benefits   | ​ |   |             6,519 | ​ |   |             5,219 |
| Accrued professional fees and other | ​ |   |             3,147 | ​ |   |             1,517 |
| Total                               | ​ | $ |            25,592 | ​ | $ |            21,540 |

10. Royalty Purchase and Sale Agreement During the fourth quarter of 2023, the Company, through its wholly-owned subsidiary Cara Royalty Sub, LLC, a Delaware limited liability company, or Cara Royalty Sub, entered into the HCR Agreement with HCR, pursuant to which Cara Royalty Sub sold, or agreed to sell, to HCR certain of its rights to receive royalty payments, or the Royalties, due and payable to Cara Royalty Sub (as assignee of the Company) under the Maruishi Agreement and Vifor Agreement No. 2., collectively the Covered License Agreements, in exchange for up to $ 40,000 . The Company has retained all of its